Be the first to like this
During the past few years, scientific journals and government regulators have increased the scrutiny and expectations facing pharmaceutical companies looking to publish the results of their clinical trials. With this scrutiny has come a shift in focus and transparency. Gone are the days of picking and choosing favorable findings to share, but now companies are struggling with how to measure the success of their Scientific Publications groups. With ever-changing expectations and regulations, global publications leaders at pharmaceutical companies must carefully build their strategies to present findings in an ethical and transparent manner. Best Practices conducted this research in 2011 and 2007 and you will see longitudinal data where appropriate. This will allow you to see how trends in Scientific Publications have evolved in the last four years.
KEY TOPICS COVERED IN THE RESEARCH:
- Optimal structure for the global publications function
- Transition of global pub function from commercial to clinical
- Key internal stakeholders who contribute to publications strategy
- Tactics for handling publication of neutral or negative clinical trial results
- Impact of transparency guidelines on publications, planning and delivery
- Strategy changes for the new marketplace
This study was conducted through surveys and qualitative interviews with pharmaceutical and biotechnology Global Publication Strategy executives.